New ETVAX® data was presented during VASE, an international gathering dedicated to develop Shigella and ETEC vaccines
During three days in Washington, the top minds in the enteric vaccine field met to share the latest research and ideas toward making enteric vaccines a reality to advance global health. Scandinavian Biopharma was playing a key role sharing important research and development advancements.
The Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference brings together hundreds of scientists, public health professionals, immunization leaders, vaccine industry representatives, international donors, and other experts around the globe.
Dr Nils Carlin from Scandinavian Biopharma gave an update of the vaccine formulation for licensure, an overview over the accomplished clinical program and over the planned efficacy trials in phase 3. Dr. Nsofwa Sukwa, from the Centre for Infectious Disease Research in Zambia, presented results from our completed phase 1 age-descending study in Zambia where ETVAX ® was shown safe, tolerable, and immunogenic in Zambian adults and children.
PI Dr Jahangir Hossain, Medical Research Council Unit The Gambian at the London School of Hygiene & Tropical Medicine, and Professor Tom Wierzba, Wake Forest University, presented data from our large Phase IIb trial in The Gambia where all participants recently received the third and final vaccination dose. Dr Firdausi Qadri, icddr,b in Dhaka, shared surveillance data as well as data on the impact of ETEC and cholera epidemics from Bangladesh.
Cynthia Mubanga, Research fellow at Centre for Infectious Disease Research in Zambia, presented promising cross-reactivity of the ETVAX® vaccine-induced antibodies to diarrhoeagenic Escherichia coli specific antigens using microarray analysis.
This is really a conference designed to spark innovation. Children are still dying and facing long-term health consequences due to this preventable illness, and new interventions are urgently needed. For us, it is extremely important to participate in the scientific debate to accelerate the momentum for research and development in the enteric vaccine field, says Björn Sjöstrand CEO of Scandinavian Biopharma.
Lou Bourgeois, Ibrahim Khalil, Shiri Meron-Sudai, Nils Carlin, Nsofwa Sukwa, Tom Wierzba and Jahangir Hossain